Trial Profile
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Aug 2023
Price :
$35
*
At a glance
- Drugs ASTX-029 (Primary)
- Indications Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 03 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 03 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition